Neuproscan

Neuproscan is an advanced AI-powered diagnostic platform designed to detect early, pre-clinical signs of Alzheimer's disease from standard MRI scans. Its core value proposition lies in transforming neuroimaging analysis by identifying subtle biomarkers of neurodegeneration long before overt clinical symptoms appear, thereby enabling proactive intervention and personalized healthcare strategies. By leveraging deep learning algorithms trained on vast datasets, the tool significantly improves diagnostic accuracy compared to traditional radiological assessment alone, while also reducing the time and cost associated with lengthy diagnostic journeys.

Key features: The platform automates the quantification of critical brain structures, such as hippocampal volume and cortical thickness, providing precise volumetric reports. It can detect patterns of amyloid-beta and tau protein accumulation indirectly through structural changes, offering a non-invasive alternative to PET scans. The system generates comprehensive, clinician-ready reports with visual heatmaps highlighting regions of concern and longitudinal tracking capabilities to monitor disease progression over time. Integration with hospital PACS systems allows for seamless workflow adoption.

What sets Neuproscan apart is its specific focus on the pre-clinical stage, a niche not extensively covered by general neuroimaging AI tools. Its algorithms are validated against gold-standard cerebrospinal fluid and PET biomarkers, achieving high sensitivity and specificity in peer-reviewed studies. The technology is built on a proprietary convolutional neural network architecture optimized for 3D MRI data, and it offers a cloud-based API for integration into existing telemedicine or research platforms, ensuring scalability and data security compliance with standards like HIPAA and GDPR.

Ideal for neurologists, geriatricians, and radiologists in clinical practice seeking to enhance early detection protocols. It is also valuable for academic research institutions conducting longitudinal studies on aging and neurodegeneration, as well as for pharmaceutical companies running clinical trials for Alzheimer's therapeutics, where it can serve as a digital biomarker for patient stratification and treatment efficacy monitoring.

The platform operates on a freemium model, providing limited free analysis for individual practitioners or researchers, with advanced features, batch processing, and institutional licenses available through paid tiers. The free tier typically includes a few scans per month with basic reporting, while professional plans unlock full historical comparison, priority processing, and dedicated support.